Two National Guard members shot near White House
Iqvia Holdings Inc. reached a significant milestone as its stock hit a 52-week high of 228.17 USD. This achievement marks a notable point in the company’s performance over the past year, reflecting investor confidence and market strength. According to InvestingPro data, IQVIA’s current price sits just 1% below this peak, while management has been aggressively buying back shares, further supporting the stock’s momentum. Over the last 12 months, Iqvia’s stock has experienced a positive change, appreciating by 11.69%. Even more impressive is the stock’s 64% surge over the past six months. This increase underscores the company’s growth trajectory and its ability to navigate the competitive landscape effectively. With 10 analysts recently revising earnings expectations upward and InvestingPro analysis suggesting the stock is slightly undervalued, investors and market analysts will be closely monitoring Iqvia’s next moves as it continues to build on this momentum. For deeper insights into IQVIA’s financial health and growth potential, explore the comprehensive Pro Research Report available exclusively with an InvestingPro subscription.
In other recent news, IQVIA Holdings Inc. reported its third-quarter earnings for 2025, surpassing analyst expectations with an adjusted diluted earnings per share of $3.00, slightly higher than the forecast of $2.97. The company’s revenue for the quarter reached $4.1 billion, also exceeding expectations of $4.08 billion. In other developments, IQVIA appointed Nobel Prize winner Dr. William G. Kaelin Jr. to its board of directors, bringing his expertise in medicine and physiology to the company. Additionally, TD Cowen downgraded IQVIA’s stock rating from Buy to Hold, citing valuation concerns, although the price target was raised to $215.00 from $206.00. Meanwhile, Baird upgraded IQVIA’s stock rating to Outperform, raising the price target to $258.00 from $224.00, due to a moderately improving environment in the research and development sector. Elsewhere, NEXT Oncology, an Avacare business, expanded its Phase I cancer clinical trial services to Asia through a new partnership with Kansai Medical University in Osaka, Japan. This collaboration adds to NEXT Oncology’s existing global network, which includes sites in the United States, Spain, and Brazil.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.